Vident Advisory, LLC Intellia Therapeutics, Inc. Transaction History
Vident Advisory, LLC
- $3.62 Trillion
- Q2 2024
A detailed history of Vident Advisory, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 19,621 shares of NTLA stock, worth $352,981. This represents 0.01% of its overall portfolio holdings.
Number of Shares
19,621
Previous 17,488
12.2%
Holding current value
$352,981
Previous $481 Million
8.72%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding NTLA
# of Institutions
326Shares Held
88.8MCall Options Held
673KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.6MShares$209 Million2.36% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$173 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.1MShares$164 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$86.4 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$78.5 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.37B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...